Related Experiment Video
Updated: May 6, 2026
10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
21.9K
Thrombocytopenia and thrombosis: a double-edged sword
Myat Tun Lin Nyo1, Asgar Ali Kalla
1Department of Medicine, Division of Rheumatology, Medical University of Southern Africa, MEDUNSA 0204, P O Box 625, Pretoria, South Africa, mtlnyo@gmail.com.
Clinical Rheumatology
|November 8, 2013
Summary
Managing severe thrombocytopenia with bleeding and thrombosis in antiphospholipid syndrome (APS) presents significant clinical challenges. This case report highlights the difficulties and reviews literature on managing this rare but serious APS complication.
Area of Science:
- Hematology
- Rheumatology
- Clinical Medicine
Background:
- Antiphospholipid syndrome (APS) is an autoimmune disorder associated with a high risk of thrombosis.
- Severe thrombocytopenia with bleeding is a rare but serious complication of APS.
- Current management strategies for this specific APS presentation lack evidence-based guidelines.
Observation:
- This case report focuses on a patient presenting with severe thrombocytopenia, bleeding, and life-threatening thrombotic events.
- The co-occurrence of severe thrombocytopenia and major thrombosis in APS poses a significant clinical dilemma.
Findings:
- Hemorrhage is an infrequent but serious complication of APS, often linked to severe thrombocytopenia.
- There is a lack of evidence-based guidelines for managing patients with concurrent severe thrombocytopenia and major thrombotic manifestations in APS.
Implications:
- This case highlights the critical need for further research into effective management strategies for this complex APS presentation.
- Clinicians face considerable challenges in balancing anticoagulation for thrombosis with the risk of bleeding due to thrombocytopenia.
Related Concept Videos
01:24Disorders of Hemostasis
2.7K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.7K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
01:30Venous Thrombosis I: Introduction
831
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
831
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
01:29Venous Thrombosis III: Interprofessional Care
482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.8K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.8K